Sheila A. Doggrell
Division of Health Practice
Auckland University of Technology--Akoranga Campus
Northcote
Auckland
New Zealand
Name/email consistency: high
- Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation. Doggrell, S.A. Expert. Opin. Pharmacother (2006)
- Nitrone spin on cerebral ischemia. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006)
- Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease. Doggrell, S.A. Expert. Opin. Investig. Drugs (2006)
- Ceramide as a target in emphysema. Doggrell, S.A. Expert Opin. Ther. Targets (2006)
- Bradykinin B2 receptors as a target in diabetic nephropathy. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006)
- New targets in and potential treatments for cholesterol gallstone disease. Doggrell, S.A. Curr. Opin. Investig. Drugs (2006)
- Conivaptan Yamanouchi. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005)
- Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005)
- Rho-kinase inhibitors show promise in pulmonary hypertension. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005)
- Ximelagatran--recent comparisons with warfarin. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005)
- Taking the 20-HETE out of the cardiovascular system: the potential of 20-HETE synthesis inhibitors. Doggrell, S.A. Curr. Opin. Investig. Drugs (2005)
- Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- More support for high-dose atorvastatin in coronary artery disease. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- Pregabalin or morphine and gabapentin for neuropathic pain. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- Potential of growth hormone-releasing hormone antagonists (JV-1-36 and JV-1-42) for the treatment of brain tumours. Doggrell, S.A. Expert. Opin. Investig. Drugs (2005)
- Recent findings with docetaxel in postoperative treatment for breast cancer. Doggrell, S.A. Expert. Opin. Pharmacother (2005)
- Inflammation, the key to much pathology. Doggrell, S.A. Drug News Perspect. (2005)
- Highlights from the First International Conference in Vascular Medicine, held August 26-28, 2005, in Melbourne, Australia. Vascular medicine in Australia and Germany. Doggrell, S.A. Drug News Perspect. (2005)
- Urotensin-II and the cardiovascular system--the importance of developing modulators. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- Efalizumab for psoriasis?. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- The endothelin system and its role in acute myocardial infarction. Doggrell, S.A. Expert Opin. Ther. Targets (2004)
- Vascular biology support for the use of bevacizumab in colorectal cancer. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- Sarpogrelate: cardiovascular and renal clinical potential. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- Intrathecal ziconotide for refractory pain. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- Is RGS-2 a new drug development target in cardiovascular disease?. Doggrell, S.A. Expert Opin. Ther. Targets (2004)
- Dawn of Aurora kinase inhibitors as anticancer drugs. Doggrell, S.A. Expert. Opin. Investig. Drugs (2004)
- Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents. Doggrell, S.A. Expert. Rev. Cardiovasc. Ther (2004)
- Tolvaptan (Otsuka). Doggrell, S.A. Curr. Opin. Investig. Drugs (2004)
- ETC-588 (Pfizer). Doggrell, S.A. Curr. Opin. Investig. Drugs (2004)